FluBlok — Competitive Intelligence Brief

FluBlok (FluBlok) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

marketed Recombinant protein vaccine Influenza hemagglutinin (HA) Immunology / Infectious Disease Biologic

Target snapshot

FluBlok (FluBlok) — The University of Hong Kong. FluBlok is a recombinant influenza vaccine that stimulates immune response against influenza virus surface antigens.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FluBlok TARGET	FluBlok	The University of Hong Kong	marketed	Recombinant protein vaccine	Influenza hemagglutinin (HA)
Meningococcal B (Bexsero)	Meningococcal B (Bexsero)	University of Sao Paulo General Hospital	marketed	Recombinant protein vaccine	Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	Novavax	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein
Recombinant influenza hemagglutinin	Recombinant influenza hemagglutinin	Vaxine Pty Ltd	marketed	Recombinant protein vaccine	Influenza hemagglutinin
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
Licensed 4CMenB vaccine	Licensed 4CMenB vaccine	University of Adelaide	marketed	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens
NVX-CoV2373 + NVX-CoV2515	NVX-CoV2373 + NVX-CoV2515	Novavax	phase 3	Recombinant protein vaccine	SARS-CoV-2 spike protein (original strain and Omicron variant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

1. GlaxoSmithKline · 6 drugs in this class
2. Novavax · 5 drugs in this class
3. Vaxine Pty Ltd · 2 drugs in this class
4. D'Or Institute for Research and Education · 2 drugs in this class
5. Protein Sciences Corporation · 2 drugs in this class
6. Henogen · 1 drug in this class
7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
9. National Vaccine and Serum Institute, China · 1 drug in this class
10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class